biib021
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00345189)
Timeline
Indications
Mechanism of action
HSP90AB2P inhibitor
- Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
ATP binding pocket
Chemistry & pharmacology
Loading structure…
SMILES
COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C- Mol. weight
- 318.77 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL467399 ↗
Also known as
- 6-chloro-4mdmpa
- 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9h-purin-2-ylamine
- biib021
- biib021
- biib021
- biib021
- cnf2024
- cnf2024
- cnf2024
- cnf 2024
- cnf-2024
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01004081 | Phase 2 | Nov 1, 2009 | Biogen |
| NCT01017198 | Phase 1 | Nov 1, 2009 | Biogen |
| NCT00618319 | Phase 2 | Feb 1, 2008 | Biogen |
| NCT00618735 | Phase 1 | Feb 1, 2008 | Biogen |
| NCT00412412 | Phase 1 | Dec 1, 2007 | Biogen |
| NCT00345189 | Phase 1 | Feb 1, 2006 | Biogen |
| NCT00344786 | Phase 1 | Feb 1, 2006 | Biogen |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 7 | 7 | 2 | 2006 |
1 organizations
Page 1 / 1